Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.

Learning Objectives

  • Pulmonary arterial hypertension as a clinical condition
  • Applying proteomics to risk stratification
  • Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition

Christopher Rhodes, MA, Cantab, PhD

Christopher Rhodes, MA, Cantab, PhD

Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London

Martin R. Wilkins

Martin R. Wilkins

Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London

Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics

A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins

Share with colleagues

More webinars

WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease 

Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.

Learn more

WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies 

High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.

Learn more

WebinarDetecting growing tumors through changes in the plasma proteome 

In this GEN webinar, Nebojsa Janjic, PhD, will discuss the need for a reliable blood-based screening method capable of detecting cancers earlier. During the webinar, he will highlight results from a study involving researchers from SomaLogic and the University of Colorado School of Medicine that used a test capable of measuring 5000 proteins simultaneously.

Learn more

Explore webinars in our interactive viewer